Imaging kidney sodium levels using MRI
Kidney Sodium Functional Imaging: Evaluation of Kidney Medullary Sodium Content Using 23Na MRI in Kidney Disease
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · NCT05014178
This study is testing if a special MRI can show differences in sodium levels in the kidneys of people with various kidney diseases to help improve their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (other) |
| Locations | 1 site (London, Ontario) |
| Trial ID | NCT05014178 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the corticomedullary gradient in patients with various kidney diseases by utilizing sodium Magnetic Resonance Imaging (MRI). Approximately 200 participants will be recruited from the London Health Sciences Regional Renal Program, where they will undergo a sodium MRI scan of their kidneys along with blood pressure measurements, urine samples, and blood work. The study seeks to determine if the sodium gradient in the kidneys is altered across a spectrum of kidney diseases, which could enhance management strategies for these conditions.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with chronic kidney disease stages 1-5 or healthy controls without kidney disease.
Not a fit: Patients who are pregnant, breastfeeding, or have contraindications to MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive method to assess kidney function and improve management of chronic kidney diseases.
How similar studies have performed: While the use of sodium MRI in kidney imaging is a novel approach, similar imaging techniques have shown promise in assessing kidney function in other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * For healthy controls: lack of kidney disease, heart failure, liver cirrhosis and peripheral edema * For CKD stage 1-5: Estimated GFR \< 90 mL/min/1.73m² * For patients on maintenance hemodialysis or peritoneal dialysis: more than 3 months duration of therapy Exclusion Criteria: * Pregnant, breastfeeding or intending pregnancy * Contraindication to MRI * Inability to tolerate MRI due to patient size and/or known history of claustrophobia. * Mechanically implanted, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, tattoos, shunt, surgical staples (including clips or metallic sutures and/or ear implants.)
Where this trial is running
London, Ontario
- Victoria Hospital, London Health Sciences Centre — London, Ontario, Canada (RECRUITING)
Study contacts
- Study coordinator: Christopher W McIntyre, MD
- Email: christopher.mcintyre@lhsc.on.ca
- Phone: 5196858500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Chronic Kidney Disease, Nephrolithiasis, ADPKD, cortico-medullary gradient